Caribou Biosciences (CRBU)

Company Profile

Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve antitumor activity. Caribou is advancing a pipeline of off-the-shelf cell therapies from its CAR-T and CAR-NK platforms as readily available treatments for patients with hematologic malignancies and solid tumors.

Company profile

Ticker

CRBU

Exchange

Incorporated

Location

Fiscal year end

Sector

Manufacturing > Biological Product (except Diagnostic) Manufacturing

Industry (SIC)

Biological Products, (No Diagnostic Substances)

AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Bio-Techne • Sana Biotechnology • Ginkgo Bioworks • Exelixis ...

SEC CIK

0001619856

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Antler Holdco, LLC • Arboreal Holdco, LLC • Biloba Holdco, LLC • Microbe Holdco, LLC ...

IRS number

453728228

CRBU stock data

1M 1Y 5Y

Analyst ratings and price targets

Last 3 months

Average target

$28.50

Low target

$25.00

High target

$32.00

Latest filings (excl ownership)

View all

9 May 23

Caribou Biosciences Reports First Quarter 2023 Financial Results and Provides Business Update

9 May 23

DEFA14A

Additional proxy soliciting materials

28 Apr 23

Annual report to shareholders

28 Apr 23

8-K

Regulation FD Disclosure

4 Apr 23

8-K

Regulation FD Disclosure

29 Mar 23

8-K

Regulation FD Disclosure

Registration of securities for employees

9 Mar 23

Latest ownership filings

View all

Dara Richardson-Heron

Financial summary

Financial statements Chart CRBU financial data

Quarter (USD)	Mar 23	Dec 22	Sep 22	Jun 22
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	52.79 mm	52.79 mm	52.79 mm	52.79 mm	52.79 mm	52.79 mm
Cash burn (monthly)	1.86 mm	7.91 mm	10.37 mm	9.72 mm	9.31 mm	8.10 mm
Cash used (since last report)	3.57 mm	15.12 mm	19.83 mm	18.59 mm	17.81 mm	15.49 mm
Cash remaining	49.22 mm	37.67 mm	32.96 mm	34.20 mm	34.98 mm	37.30 mm
Runway (months of cash)	26.4	4.8	3.2	3.5	3.8	4.6

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q1 2023

CRBU institutional ownership history Ownership history

82.3% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	123	132	-6.8%
Opened positions	13	31	-58.1%
Closed positions	22	11	+100.0%
Increased positions	48	35	+37.1%
Reduced positions	32	37	-13.5%

13F shares	Current	Prev Q	Change
Total value	234.63 bn	267.06 bn	-12.1%
Total shares	50.49 mm	49.50 mm	+2.0%
Total puts	19.10 k	6.80 k	+180.9%
Total calls	18.10 k	91.40 k	-80.2%
Total put/call ratio	1.1	0.1	+1318.4%

Largest owners	Shares	Value	Change
Partner Fund Management	5.01 mm	$26.61 bn	+12.4%
BLK Blackrock	4.75 mm	$25.25 bn	+0.7%
STT State Street	3.36 mm	$17.82 bn	+4.9%
Rachel E. Haurwitz	3.35 mm	$37.21 mm	0.0%
Avidity Partners Management	2.76 mm	$14.65 bn	-4.3%
Rokos Capital Management	2.75 mm	$14.09 bn	0.0%
BAC Bank Of America	2.63 mm	$13.98 bn	+42.8%
Vanguard	2.61 mm	$13.84 bn	+1.0%
Farallon Capital Partners	2.58 mm	$41.11 mm	0.0%
Elmwood Wealth Management	2.36 mm	$12.55 bn	0.0%

Largest transactions	Shares	Bought/sold	Change
BAC Bank Of America	2.63 mm	+788.48 k	+42.8%
Partner Fund Management	5.01 mm	+552.34 k	+12.4%
Pictet Asset Management	2.07 mm	-487.70 k	-19.1%
Citadel Advisors	282.85 k	+244.96 k	+646.4%
Millennium Management	0.00	-240.04 k	EXIT
Norges Bank	0.00	-216.30 k	EXIT
International Biotechnology Trust	457.89 k	+200.00 k	+77.6%
Shelton Capital Management	0.00	-160.70 k	EXIT
STT State Street	3.36 mm	+156.40 k	+4.9%
Avidity Partners Management	2.76 mm	-124.00 k	-4.3%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

CRBU insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
20 Mar 23	Rachel E. Haurwitz	Common Stock	Option exercise	Acquire M	No	No	2.96	10,000	29.60 k	30,000
20 Mar 23	Rachel E. Haurwitz	Option to purchase Common Stock Common Stock	Option exercise	Dispose M	No	No	2.96	10,000	29.60 k	106,350
21 Feb 23	Johnson David Lee	Option to purchase Common Stock Common Stock	Grant	Acquire A	No	No	6.12	21,500	131.58 k	21,500
21 Feb 23	Jason O'Byrne	Option to purchase Common Stock Common Stock	Grant	Acquire A	No	No	6.12	131,000	801.72 k	131,000
21 Feb 23	Nancy Whiting	Option to purchase Common Stock Common Stock	Grant	Acquire A	No	No	6.12	21,500	131.58 k	21,500
21 Feb 23	Braunstein Scott	Option to purchase Common Stock Common Stock	Grant	Acquire A	No	No	6.12	21,500	131.58 k	21,500